港股异动 | 科伦博泰生物(06990)涨超5% 与默沙东合作的TROP2 ADC全球III期研究达成主要终点

智通财经
May 21

智通财经APP获悉,科伦博泰生物(06990)涨超5%,截至发稿,涨3.3%,报451.4港元,成交额1.66亿港元。

消息面上,近日,据科伦博泰生物官微消息,默沙东宣布,与公司合作开发的在研TROP2靶向抗体药物偶联物(ADC)sacituzumab tirumotecan(sac-TMT),在针对某些晚期或复发性子宫内膜癌患者的关键性III期TroFuse-005试验中,达到了总生存期(OS)和无进展生存期(PFS)的主要终点。

TroFuse-005是首个针对该类患者、与化疗相比在总生存期(OS)和无进展生存期(PFS)两方面均显示出统计学显著改善的全球III期试验,也是首个且唯一一个在此类子宫内膜癌患者中实现这一突破的ADC药物。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10